Precigen Inc PGEN

NAS: PGEN | ISIN: US74017N1054   19:59
1,395 USD (-0,36%)
(-0,36%)   19:59

24 april 2024 · Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting · Persbericht

24 april 2024 · Actym Therapeutics Appoints Thomas Smart as CEO · Persbericht

28 maart 2024 · Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th · Persbericht

19 maart 2024 · Precigen Reports Full Year 2023 Financial Results and Business Updates · Persbericht

12 maart 2024 · Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

5 maart 2024 · Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th · Persbericht

6 februari 2024 · Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

16 januari 2024 · Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission · Persbericht

8 januari 2024 · Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

18 december 2023 · Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

9 november 2023 · Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs · Persbericht

7 november 2023 · Precigen to Participate in the Stifel 2023 Healthcare Conference · Persbericht

19 september 2023 · Precigen to Participate in Upcoming Leading Investor and Industry Conferences · Persbericht

14 augustus 2023 · Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements · Persbericht

9 augustus 2023 · Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 · Persbericht

9 augustus 2023 · Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval · Persbericht

3 augustus 2023 · Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th · Persbericht

20 juni 2023 · Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

5 juni 2023 · Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients · Persbericht

3 juni 2023 · Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers · Persbericht

Mijn selecties